Morepen Laboratories Receives Show Cause Notice from GST Authority
Morepen Laboratories received a Show Cause Notice from GST Authority regarding an alleged excess GST refund claim of ₹117,94,03,452. The company will submit the required information.
The impact is medium because while the company is contesting the notice, there is a potential financial liability if the claim is not resolved favorably. The amount is also significant.
The announcement discusses a legal challenge in the form of a show cause notice, which could potentially lead to financial implications.
* Morepen Laboratories has received a Show Cause Notice (SCN) dated December 2, 2025, from the Office of the Commissioner Central GST & Central Excise Commissionerate, Shimla, received on December 3, 2025. * The SCN pertains to a discrepancy in the application for a refund of accumulated ITC on account of zero-rated supply for the financial years 2020 to 2024. * The company had applied under Rule 89(4) of the CGST Rules, 2017, instead of Rule 89(4B). * The SCN alleges a violation of Section 54 of the CGST Act, 2017, with an alleged excess GST refund claim of ₹117,94,03,452/- * Morepen Laboratories contends that it claimed the refund as per GST Act provisions and believes the SCN is without merit. * The company will submit necessary information, documents, and explanations to the GST authority within the prescribed period and is also seeking legal advice to protect its interests.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.